Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy and Group Finance Director Marcus Karia will depart. The moves come 15 months after the firm announced a string of departures that included CEO Joe Anderson, Chairman Jonathan Peacock and Art Pappas, a non-executive director. Two months later, in June 2020, the firm named Schetter, then an entrepreneur-in-residence, managing director.
Chin was investment director at the venture capital firm in 2016-20. Since his departure, he has remained on the boards of Harpoon Therapeutics Inc. (NASDAQ:HARP), Imara Inc. (NASDAQ:IMRA) and Iterum Therapeutics plc (NASDAQ:ITRM). He will be based in New York...